Century Therapeutics (NASDAQ:IPSC) Price Target Lowered to $7.00 at Chardan Capital

Century Therapeutics (NASDAQ:IPSC) had its target price reduced by Chardan Capital from $11.00 to $7.00 in a research note issued to investors on Monday morning,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

A number of other equities research analysts also recently issued reports on IPSC. Piper Sandler lowered their price objective on Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating on the stock in a research report on Thursday, March 20th. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Century Therapeutics in a research report on Wednesday, January 22nd. Finally, Guggenheim cut their price objective on Century Therapeutics from $12.00 to $5.00 and set a “buy” rating for the company in a report on Friday. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $5.00.

Century Therapeutics Trading Up 5.2 %

Century Therapeutics stock opened at $0.58 on Monday. The firm has a market capitalization of $49.63 million, a price-to-earnings ratio of -0.32 and a beta of 1.75. The firm has a 50 day simple moving average of $0.74 and a 200 day simple moving average of $1.15. Century Therapeutics has a 1-year low of $0.52 and a 1-year high of $4.50.

Century Therapeutics (NASDAQ:IPSC) last issued its earnings results on Wednesday, March 19th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.02. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. The business had revenue of $4.18 million during the quarter, compared to the consensus estimate of $0.67 million. On average, equities research analysts forecast that Century Therapeutics will post -1.61 EPS for the current year.

Hedge Funds Weigh In On Century Therapeutics

A number of large investors have recently modified their holdings of IPSC. Marshall Wace LLP purchased a new stake in Century Therapeutics in the fourth quarter worth approximately $36,000. Jane Street Group LLC grew its holdings in shares of Century Therapeutics by 166.2% during the 4th quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock valued at $49,000 after purchasing an additional 29,992 shares during the last quarter. Two Sigma Advisers LP purchased a new position in Century Therapeutics in the 4th quarter worth $52,000. Sei Investments Co. bought a new stake in Century Therapeutics in the fourth quarter worth $53,000. Finally, Barclays PLC grew its stake in shares of Century Therapeutics by 283.6% during the third quarter. Barclays PLC now owns 61,945 shares of the company’s stock valued at $106,000 after buying an additional 45,797 shares during the last quarter. 50.20% of the stock is owned by hedge funds and other institutional investors.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.